POLB 001 [Not yet assigned, Not yet assigned] , Teclistamab [Teclistamab, Teclistamab] clinical trials

Testing a new treatment to prevent severe immune reactions in people with multiple myeloma taking teclistamab

This study tests a new medicine called POLB 001. It aims to reduce severe immune reactions (CRS) in people with myeloma (blood cancer) who are starting a treatment called teclistamab. We want to see if POLB 001 can make teclistamab safer.